Hypertension in hemodialysis patients treated with atenolol or lisinopril: A randomized controlled trial

Nephrology Dialysis Transplantation

Volumn 29, Issue 3, 2014, Pages 672-681

  Agarwal, Rajiv ^a   Sinha, Arjun D ^a   Pappas, Maria K ^a   Abraham, Terri N ^a   Tegegne, Getachew G ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Hemodialysis; Hypertension; Randomized trial

Indexed keywords

ATENOLOL; LISINOPRIL; ANTIHYPERTENSIVE AGENT;

ABDOMINAL PAIN; ADULT; ALLERGIC REACTION; ANEMIA; ANGINA PECTORIS; ARTICLE; ASTHMA; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG SAFETY; FAINTNESS; FEMALE; FRACTURE; GANGRENE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOGLYCEMIA; HYPOTENSION; INFECTION; INTESTINE PERFORATION; LEFT VENTRICULAR MASS INDEX; LEG PAIN; LETHARGY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONCARDIAC CHEST PAIN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PSEUDOGOUT; RANDOMIZED CONTROLLED TRIAL; SHOULDER DISLOCATION; SUICIDAL IDEATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; AGED; CHEMICALLY INDUCED; COMPLICATION; DOUBLE BLIND PROCEDURE; EARLY TERMINATION OF CLINICAL TRIAL; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; TREATMENT FAILURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; LISINOPRIL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RENAL DIALYSIS; TREATMENT FAILURE;

EID: 84895747965     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft515     Document Type: Article

References (22)

1. Agarwal R, Nissenson AR, Batlle D et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-297
2. Zoccali C, Benedetto FA, Tripepi G et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int 1998; 53: 1078-1084
3. Amar J, Vernier I, Rossignol E et al. Influence of nycthemeral blood pressure pattern in treated hypertensive patients on hemodialysis. Kidney Int 1997; 51: 1863-1866
4. Agarwal R Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension 2010; 56: 512-517
5. Agarwal R, Alborzi P, Satyan S et al. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53: 500-507
6. Blankestijn PJ, Ligtenberg G Volume-independent mechanisms of hypertension in hemodialysis patients: clinical implications. Semin Dial 2004; 17: 265-269
7. Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015
8. Agarwal R, Sinha AD Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53: 860-866
9. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010
10. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458
11. Agarwal R Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999; 55: 1528-1535
12. Agarwal R, Lewis RR, Davis JL et al. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 2001; 38: 1245-1250
13. Li Z, Lacson E, Jr, Lowrie EG et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48: 606-615
14. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811-817
15. Zannad F, Kessler M, Lehert P et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324
16. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebocontrolled trial. J Am Coll Cardiol 2003; 41: 1438-1444
17. Lang CC, Stein CM, Brown RM et al. Attenuation of isoproterenolmediated vasodilatation in blacks. N Engl J Med 1995; 333: 155-160
18. Stein CM, Lang CC, Singh I et al. Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks. Additive mechanisms leading to enhanced vascular reactivity. Hypertension 2000; 36: 945-951
19. Weir MR, Chrysant SG, McCarron DA et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998; 31: 1088-1096
20. Chrysant SG, Danisa K, Kem DC et al. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension 1979; 1: 136-141
21. Converse RL, Jr, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
22. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359